Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Antibe Therapeutics Inc. (V:ATE)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 15 Prince Arthur Ave
Tel: N/A
IR: See website
Key People
Walter M. Macnee
Independent Chairman of the Board
Daniel Legault
President, Chief Executive Officer, Secretary, Director
John L. Wallace
Founder, Chief Scientific Officer, Director
Alain S Wilson
Chief Financial Officer
Jeremy Grushcow
Executive Vice President - Strategic Development
David Vaughan
Chief Development Officer
Business Overview
Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.
Financial Overview
For the nine months ended 31 December 2019, Antibe Therapeutics Inc revenues increased 7% to C$7.6M. Net loss increased 48% to C$12.4M. Revenues reflect United States segment increase of 46% to C$2.6M, Europe segment increase of 51% to C$306K. Higher net loss reflects Development costs increase from C$2.1M to C$4.5M (expense), Stock-based Compensation in SGA increase of 55% to C$2.1M (expense).
Employees: 3 as of Mar 31, 2013
Reporting Currency: Canadian Dollars
Enterprise value: $227.91M as of Dec 31, 2019
Annual revenue (TTM): $10.07M as of Dec 31, 2019
EBITDA (TTM): -$16.06M as of Dec 31, 2019
Net annual income (TTM): -$16.84M as of Dec 31, 2019
Free cash flow (TTM): -$9.38M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 301,110,550 as of May 25, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization